ADVFN - Advanced Financial Network.
HOME» NASDAQ » V » VICL Stock Price » VICL Stock News

Vical Share News

 Vical Incorporated (mm) Stock Price
VICL Stock Price
 Vical Incorporated (mm) Stock Chart
VICL Stock Chart
 Vical Incorporated (mm) Stock News
VICL Stock News
 Vical Incorporated (mm) Company Information
VICL Company Information
 Vical Incorporated (mm) Stock Trades
VICL Stock Trades

Biopharmaceutical Co Vical Prices 13.3M Share Offering At 12% Discount

DOW JONES NEWSWIRES Biopharmaceutical developer Vical Inc.'s (VICL) public offering of 13.3 million shares priced at a 12% discount from Thursday's close. Shares were recently trading at $3.79, slightly above the offering price of $3.75. Vical develops gene-based treatments for cancer as well as vaccines for infectious diseases. Last year, it signed a $130 million licensing deal with Japan's Astellas Pharma Inc. (4503.TO, ALPMY) to develop and sell its TransVax cytomegalovirus vaccine. Like many development-stage drug makers, it posts frequent losses. The company, which had about 73.7 million outstanding shares as of Nov. 1, outlined plans to offer stock late Thursday but didn't detail how many shares it intended to offer. The firm expects to use the proceeds for general corporate purposes, including clinical trial expenses, research and development and other working capital. In November, Vical said it swung to a third-quarter profit on a large increase in license and royalty revenue. -By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108;;

Stock News for Vical (VICL)
05/21/201506:30:00Vical Announces Completion of Enrollment in Phase 2 Clinical...
05/08/201517:15:04Quarterly Report (10-q)
05/08/201511:27:21Current Report Filing (8-k)
05/08/201506:30:00Vical Reports First Quarter 2015 Financial Results and Progress...
05/01/201519:41:02Zacks Lowers Vical to Hold (VICL)
05/01/201506:30:00Vical Announces News Release and Conference Call Schedule for...
04/27/201512:19:49Statement of Changes in Beneficial Ownership (4)
04/22/201506:30:00Vical to Manufacture HIV Vaccines for Clinical Evaluation by...
04/21/201506:30:00Vical Announces Presentation of Preclinical Data for Congenital...
04/15/201516:13:21Statement of Changes in Beneficial Ownership (4)
04/15/201516:08:31Statement of Changes in Beneficial Ownership (4)
04/15/201516:03:16Statement of Changes in Beneficial Ownership (4)
04/13/201515:28:47Confidential Treatment Order (ct Order)
04/08/201512:32:43Additional Proxy Soliciting Materials (definitive) (defa14a)
04/08/201512:30:37Proxy Statement (definitive) (def 14a)
04/01/201516:35:11Statement of Changes in Beneficial Ownership (4)
03/25/201517:17:01Current Report Filing (8-k)
03/25/201516:15:00Vical Expands Infectious Disease Portfolio With Novel Antifungal...
03/05/201506:00:00Vical to Present at the 27th Annual ROTH Conference
02/26/201506:33:09Vical EPS in-line, beats on revenue

Vical and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations